EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Analysis of Medical Costs of Melanoma Using a Japanese National Database

Meiko Goto, Hiroyuki Goto iD, Tsubasa Bito, Ryota Kawai iD, Sho Hiroyasu iD, Ayumi Shintani, Daisuke Tsuruta iD

The Journal of Dermatology · 2026

DOI: 10.1111/1346-8138.70227 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Journal of Dermatology, 2026. Verfasst von Meiko Goto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Immune Checkpoint Inhibitors, Health Care Costs. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The advent of immune checkpoint inhibitors (ICIs) and targeted therapeutic agents (TTAs) has improved melanoma treatment. With the ongoing development of novel drugs, treatment options are expected to expand further. However, this is also anticipated to increase the financial burden on patients. Changes in medical costs for melanoma patients have not yet been examined in Japan. Therefore, we herein conducted a retrospective observational study using data from a Japanese nationwide database. The dataset comprised 14 727 patients diagnosed with melanoma between April 2008 and June 2023. The mean monthly cost per patient was calculated and changes were evaluated. The results obtained showed that the mean monthly cost per patient has consistently increased, and a breakdown revealed that drug costs for ICIs and TTAs accounted for a significant percentage of these costs. Furthermore, the usage rates of ICIs and TTAs have steadily increased since their approval in 2014, with a notable rise being observed in 2018 when adjuvant therapies were approved in Japan. An interrupted time series analysis further confirmed a significant increase in medical costs around 2018. While ICIs and TTAs represent major advances in melanoma treatment, their increasing use underscores the need for a careful evaluation of both clinical benefits and economic sustainability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsImmune Checkpoint InhibitorsHealth Care CostsHumansJapanRetrospective StudiesDatabases, FactualDrug CostsFemaleMolecular Targeted TherapyMaleChemotherapy, AdjuvantMiddle AgedAgedEast Asian People

Stichwörter der Autor:innen

adjuvant therapymedical costsmelanoma

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
  • Department of Medical Statistics, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.

ORCID-Profile: Hiroyuki Goto, Ryota Kawai, Sho Hiroyasu, Daisuke Tsuruta

Zitieren

APA

Goto, M., Goto, H., Bito, T., Kawai, R., Hiroyasu, S., Shintani, A., & Tsuruta, D. (2026). Analysis of Medical Costs of Melanoma Using a Japanese National Database. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.70227

Vancouver

Goto M, Goto H, Bito T, Kawai R, Hiroyasu S, Shintani A, et al. Analysis of Medical Costs of Melanoma Using a Japanese National Database. The Journal of Dermatology. 2026. doi:10.1111/1346-8138.70227

BibTeX
@article{Goto2026,
  author = {Goto, Meiko and Goto, Hiroyuki and Bito, Tsubasa and Kawai, Ryota and Hiroyasu, Sho and Shintani, Ayumi and Tsuruta, Daisuke},
  title = {Analysis of Medical Costs of Melanoma Using a Japanese National Database},
  journal = {The Journal of Dermatology},
  year = {2026},
  doi = {10.1111/1346-8138.70227}
}
Kostenlos starten →